Immunic, Inc. (IMUX)
| Market Cap | 102.47M +30.2% |
| Revenue (ttm) | n/a |
| Net Income | -111.57M |
| EPS | -4.00 |
| Shares Out | 13.64M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 244,421 |
| Open | 7.70 |
| Previous Close | 7.80 |
| Day's Range | 7.37 - 7.78 |
| 52-Week Range | 5.06 - 17.43 |
| Beta | 1.45 |
| Analysts | Strong Buy |
| Price Target | 43.09 (+473.77%) |
| Est. Earnings | Nov 12, 2026 |
About IMUX
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patien... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for IMUX stock is "Strong Buy." The 12-month stock price target is $43.09, which is an increase of 473.77% from the latest price.
News
Immunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026
NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced th...
Immunic initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Immunic (IMUX) with an Overweight rating. Immunic offers attractive risk/reward ahead of anticipated December 2026 Phase 3 RMS readouts for vidofludimus calcium...
Immunic initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Yanni Souroutzidis initiated coverage of Immunic (IMUX) with an Overweight rating.
Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting
– New Phase 2 CALLIPER Open-Label Extension Data Support Durability of Disability Outcomes Observed During the Double-Blind Period With Continued Vidofludimus Calcium Treatment; Safety and Tolerabilit...
Immunic Slides: Investor presentation
Immunic has posted slides in relation to its latest quarterly earnings report, which was published on October 19, 2026.
Immunic appoints Jaa Roberson as chief people officer
Immunic (IMUX) announced the appointment of Jaa Roberson as chief people officer, or CPO, effective immediately. Roberson will report directly to CEO Erik Lundgren and will serve as a member…
Immunic Appoints Jaa Roberson as Chief People Officer
– Appointment Supports Immunic's Strategy to Build a Leading Multiple Sclerosis Organization Ahead of Potential Transition to Fully Integrated Commercial Company – NEW YORK, Oct. 19, 2026 /PRNewswire/...
Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting
– Four Accepted Abstracts Further Characterize Investigational Vidofludimus Calcium's Profile in Multiple Sclerosis Across Long-Term Disability Outcomes, EBV-Related Immune Activity and Cognition, Nov...
Immunic Transcript: R&D Day 2026
Vidofludimus calcium is advancing through pivotal phase III trials in relapsing MS, targeting both inflammatory and neurodegenerative disease mechanisms. The therapy aims to address key unmet needs in a large, dynamic market, with strong safety, tolerability, and commercial positioning. Phase III readouts and an NDA filing are expected within the next year.
Immunic Slides: FY 2026
Immunic has posted slides in relation to its FY 2026 quarterly earnings report, which was published on September 9, 2026.
Immunic Slides: Corporate presentation
Immunic has posted slides in relation to its latest quarterly earnings report, which was published on September 4, 2026.
Immunic Slides: Investor presentation
Immunic has posted slides in relation to its latest quarterly earnings report, which was published on September 3, 2026.
Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026
NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced tha...
Immunic price target raised to $29 from $19 at Roth Capital
Roth Capital analyst Boobalan Pachaiyappan raised the firm’s price target on Immunic (IMUX) to $29 from $19 and keeps a Buy rating on the shares ahead of the Phase 3…
Immunic appoints Chitrang Dave as chief data, digital officer
Immunic (IMUX) announced the appointment of Chitrang Dave as chief data and digital officer, effective immediately. Dave will report directly to CEO Erik Lundgren and will serve as a member…
Immunic Appoints Chitrang Davé as Chief Data and Digital Officer
– New C-Suite Role and Appointment Underscore Commitment to Building a Strong, Commercial-Ready Data Ecosystem, in Preparation for Potential NDA Submission and Commercialization – NEW YORK, Sept. 1, 2...
Immunic initiated with an Outperform at Wedbush
Wedbush analyst Martin Fan initiated coverage of Immunic (IMUX) with an Outperform rating and $45 price target Immunic is a clinical-stage biopharmaceutical company developing immune modulators for im...
Immunic Earnings release: Q2 2026
Immunic released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Immunic Quarterly report: Q2 2026
Immunic has published its Q2 2026 quarterly earnings report on August 11, 2026.
Immunic reports Q2 EPS (80c), consensus ($1.16)
“During the second quarter, we continued to execute across our late-stage development priorities as we advance toward what we believe will be a transformational period for Immunic (IMUX),” said Erik…
Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
– Leadership Team Expanded with Key Executive Appointments, Including Chief Executive Officer, Chief Medical Officer and Chair of the Board of Directors, to Support Clinical Development, as well as ND...
Immunic Appoints Elena Ridloff to Board of Directors
– Appointment Strengthens Board with Financial, Capital Markets and Commercial Leadership Expertise as the Company Approaches Pivotal Phase 3 ENSURE Readout in Relapsing Multiple Sclerosis as well as ...
Immunic Slides: Investor presentation
Immunic has posted slides in relation to its latest quarterly earnings report, which was published on July 14, 2026.
Immunic to Participate in Investor Conferences in July
NEW YORK, July 9, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced pa...
Immunic to Participate in Investor, Industry and Scientific Conferences in June
NEW YORK, June 10, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced pa...